JUL 03, 2022 4:00 PM PDT

Experimental Alopecia Treatment Regrows Hair from Dormant Follicles

WRITTEN BY: Annie Lennon

A newly-discovered signaling molecule known as SCUBE3 may be able to stimulate hair growth in those with androgenetic alopecia, also known as male-pattern baldness in men. The corresponding study was published in Developmental Cell

Androgenetic alopecia affects around 50 million men and 30 million women in the US. Currently, drugs known as finasteride and minoxidil are approved by the US Food and Drug Administration (FDA) to treat the condition. However, finasteride has only been approved for men, and both drugs are not universally effective. They also must be taken daily to maintain their effects. 

It has been known for some time that dermal papilla cells- specialized signal-making fibroblasts at the bottom of each hair follicle- send signals that either keep follicles dormant or trigger new growth. In people with androgenetic alopecia, dermal papilla cells malfunction, thus reducing signaling activity. Until now, the genetic basis for activating these cells has remained unknown. 

In the present study, researchers studied a mouse model of hyperactive dermal papilla cells and excessive hair. In doing so, they found that the SCUBE3 signaling molecule, which is naturally produced by the dermal papilla cells, is key for signaling hair stem cells to divide and generate new hair growth. In mouse experiments, they found that microinjections of SCUBE3 can grow new hair from dormant human hair follicles implanted in mice. 

"There is a strong need for new, effective hair loss medicines, and naturally occurring compounds that are normally used by the dermal papilla cells present ideal next-generation candidates for treatment," said Maksim Plikus, Ph.D., University of California- Irvine professor of developmental & cell biology and one of the study’s authors, “Our test in the human hair transplant model validates the preclinical potential of SCUBE3."

 

Sources: Science Daily, Developmental Cell

 

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
MAY 17, 2022
Cancer
Looking for an Easier Way to Scale-up Your Benchtop Cell Cultures?
MAY 17, 2022
Looking for an Easier Way to Scale-up Your Benchtop Cell Cultures?
Much has been written about scaling up cell culture for bioprocessing and other applications that require a very high de ...
MAY 19, 2022
Drug Discovery & Development
Repurposed Antibiotic Shows Promise Against COVID-19 in Mice
MAY 19, 2022
Repurposed Antibiotic Shows Promise Against COVID-19 in Mice
An antibiotic known as clofoctol has shown promise in treating SARS-CoV-2 in mice. The corresponding study was published ...
JUN 04, 2022
Drug Discovery & Development
Antibiotics Reduce Motivation to Exercise in Mice
JUN 04, 2022
Antibiotics Reduce Motivation to Exercise in Mice
Antibiotics may decrease athletes' motivation and endurance via effects on the microbiome. The corresponding study w ...
JUN 08, 2022
Coronavirus
How are you Preparing for the Next Covid Surge?
JUN 08, 2022
How are you Preparing for the Next Covid Surge?
After two years of uncertainty, we can definitely say that the coronavirus (Covid-19) has changed our everyday lives as ...
JUN 27, 2022
Cancer
A Genomic Scan Detects Cancer-Driving Mutations
JUN 27, 2022
A Genomic Scan Detects Cancer-Driving Mutations
Cancer develops when the DNA in our cells becomes altered, resulting in a gene mutation.  DNA alterations can occur ...
JUL 07, 2022
Cell & Molecular Biology
Mini-Kidneys Reveal New Insights, Treatments for Multiple Disorders
JUL 07, 2022
Mini-Kidneys Reveal New Insights, Treatments for Multiple Disorders
Researchers have been able to use animal models to study human disease, but there are clear limitations to that approach ...
Loading Comments...